4 min 
Introduction: From Early Learning to the Next Phase of Growth
By the end of the first six months in the market, an emerging pharma company has something it did not have at launch: evidence.
The market has started to reveal which HCPs are responding, where patient opportunity is concentrated, which execution strategies are gaining traction, and where friction is constraining growth. In the previous article in this series, we explored how commercial teams can use those early signals to strengthen launch performance before momentum slows.
The next challenge is more selective. Not every opportunity uncovered in those first months will materially change the brand’s trajectory. Commercial leaders need to determine which growth levers warrant greater investment — and how to pursue them without adding disproportionate cost, headcount, or operational complexity.
New capabilities in predictive intelligence, GenAI, and agentic AI are beginning to change what is possible for lean commercial organizations. For emerging pharma, the opportunity is not simply to automate more work. It is to apply greater intelligence and capacity to the few commercial decisions that matter most.
Finding the Next Growth Lever
The opportunities that drive the next phase of growth are rarely as concentrated as those that fuel initial adoption. Once the most receptive HCPs and readily identifiable patients have been reached, incremental growth may depend on solving a more varied set of commercial challenges.
For one brand, the opportunity may be identifying a small population of high-probability patients who remain difficult to find. For another, it may be uncovering the next segment of prescribers with meaningful potential, increasing appropriate patient starts among existing writers, improving persistence, or addressing an access barrier that is preventing demand from converting into therapy.
These opportunities can also exist simultaneously. That creates a particular challenge for emerging pharma: a lean commercial team must distinguish between signals that seem interesting and opportunities that are significant enough to change the growth trajectory.
The advantage is that by this stage, those decisions no longer have to be based primarily on launch assumptions. Actual patient, HCP, access, and field behavior can provide a much sharper view of where incremental growth is available – and where additional commercial effort is most likely to pay off.
Turning that evidence into action, however, requires teams to investigate more signals, connect more context, and make increasingly nuanced decisions – often without the analytical resources or specialized functions available to larger pharma organizations.
Pressure-Testing the Path to Growth
For emerging pharma, the margin for error is small. With limited resources and fewer opportunities to absorb a misstep, decisions about where to invest field time, budget, and commercial effort carry disproportionate weight.
That is where simulation can add a new layer of confidence. Digital twins and similar approaches use data-driven representations of patients, HCPs, or markets to explore how different commercial choices could affect the outcome before resources are committed.
As Shannon Campbell, a commercial pharma executive with more than 30 years of experience, points out, some of the most important assumptions to pressure-test are whether new patient starts reflect the right patient profile, what is driving adoption among current prescribers, whether patients are staying on therapy as expected, and where the next source of growth is likely to come from.
From there, teams can explore how different commercial strategies might influence those outcomes:
- What if we shifted 20% of field effort from one HCP segment to another? How might that affect patient starts or adoption?
- What if we re-allocated patient-finding resources toward a specific geography? How might that change the number of high-probability patients identified?
- What if we changed the communications channel mix for a high-potential HCP segment? How might a different combination of field and digital engagement affect ?
The result is a more informed basis for deciding not only where the next growth opportunity lies, but how to pursue it.
Expanding What a Lean Commercial Team Can
Once the path forward is clearer, the challenge shifts to executing it efficiently, particularly for teams operating with limited commercial resources.
Historically, each step from data to action required more manual work: someone had to notice a signal, investigate it, connect information across systems, determine what mattered, and then translate that finding into an action for the field or commercial team.
Newer AI capabilities are moving progressively closer to the decision itself. Predictive models can surface likely opportunities and risks. GenAI copilots can help users interrogate and synthesize that information. Agentic AI goes a step further by taking on parts of a multi-step investigation or workflow – for example, examining why a territory is deviating from plan, assembling the relevant HCP and patient context, and surfacing what deserves attention before a commercial lead has to ask the next question.
For a large organization, that can improve efficiency. For an emerging company, it can change the operating model. Work that once required a larger analytics, operations, or coordination specialists, can increasingly be supported by technology, allowing commercial experts to stay focused on judgment, strategy, and customer engagement.
In rare disease, this precision can be particularly valuable. One emerging-pharma company launching a rare-disease therapy leveraged Verix’s predictive intelligence and agentic AI workflows to identify higher-probability patient opportunities with greater precision — helping the team concentrate limited resources where they could have the greatest commercial impact.
Scaling the Next Phase of Growth
As a brand moves beyond early adoption, sustaining growth demands more sophisticated commercial decisions — often from an organization that is still intentionally lean.
The next generation of commercial intelligence can change what those teams are capable of. It gives them new ways to identify where incremental growth may come from, pressure-test competing strategies before committing resources, and translate increasingly complex market signals into focused action.
For emerging pharma, that creates a different path to scale: one where greater commercial sophistication does not have to depend on a proportionally larger organization. The next phase of growth does not have to require a bigger commercial model — but it does require a more capable one.
